TSHA News - Candlesense

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback fro...

What are the potential catalysts or red flags that could move TSHA's stock price in the next 3‑12 months? What is the expected dilution or financing requirement to support the pivotal trial? What is the estimated market size for the therapy under investigation and potential market share?

Clinical trials

24 days ago